ARTICLE | Company News
MediciNova, Kissei Pharmaceutical deal
October 24, 2011 7:00 AM UTC
Kissei will pay MediciNova $2.5 million to support development of MN-221 to treat acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). MediciNova expects top-line data from a Phase IIb trial of MN-221 in patients with acute exacerbations of asthma in 1Q12. MediciNova reported data from a Phase Ib trial of the compound in COPD in 2010 (see BioCentury, March 22, 2010). ...